A bit more news on CHR 1103 - it's in pre-clinical but has put together an impressive advisroy board.
Chromos announces independent Multiple Sclerosis Advisory Board
Chromos Molecular Systems Inc. has formed a Multiple Sclerosis (MS) Advisory Board to guide the Company's development of a promising novel treatment for MS. Comprised of nationally and internationally recognised physicians, clinicians and scientists in the MS field, the MS Advisory Board will serve as an independent panel of experts regarding the development of CHR-1103 for the acute treatment of relapses (flares) associated with MS and other follow-on indications related to MS.
Members of the Chromos MS Advisory Board are:
- Jack Antel, MD
Professor, Montreal Neurological Institute, McGill University
- Dennis Bourdette, MD
Chairman, Department of Neurology and Director of the MS Center of Oregon, Oregon Health and Sciences University
- James Bowen, MD
Medical Director of the Multiple Sclerosis Center at Evergreen Healthcare, Kirkland, Washington
- Lorne Kastrukoff, MD
Associate Professor, MS Clinic, University of British Columbia, Division of Neurology, Department of Medicine and Brain Research Centre
- Joel Oger, D.en M., FRCPC
Professor, University of British Columbia, Medicine, Pathology and Neurosciences
- Leslie P. Weiner, MD
Professor of Neurology, Keck School of Medicine, University of Southern California
"We are extremely fortunate and delighted to have the participation of this highly respected and experienced group of experts for the development of our lead product, CHR-1103," said Alistair Duncan, President and CEO of Chromos. "The ability to access and rely on such a panel of individuals is a tremendous asset for Chromos as we move forward with the clinical development of CHR-1103 for MS."
CHR-1103 is a monoclonal antibody being developed as an acute treatment for relapses (flares) associated with MS. The drug's unique mechanism of action has the potential to reduce the severity and duration of a relapse along with stemming the residual neurological damage that often accompanies a relapse, thereby slowing the overall progression of the disease.
Chromos has completed a Pre-IND Meeting with the US Food and Drug Administration (FDA) regarding the development of CHR-1103 and anticipates filling an Investigational New Drug (IND) application for CHR-1103 in 2007.
The Chromos MS Advisory Board will be instrumental in guiding the overall clinical development strategy supporting the initial indication for CHR-1103 as an acute treatment for MS relapse, but also follow-on indications surrounding long-term progression of MS and conversion to MS following initial clinical symptoms.
Source: Chromos Molecular Systems Inc.